The role of transforming growth factor-β1, -β2, and -β3 in androgen-responsive growth of NRP-152 rat prostatic epithelial cells
- 1 May 1998
- journal article
- research article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 175 (2) , 184-192
- https://doi.org/10.1002/(sici)1097-4652(199805)175:2<184::aid-jcp8>3.0.co;2-k
Abstract
We have investigated the role of autocrine/paracrine TGF-β secretion in the regulation of cell growth by androgens as demonstrated by its inhibition by two androgen response modifiers; the nonsteroidal antiandrogen hydroxyflutamide (OHF), believed to act by inhibiting androgen binding to androgen receptors, or finasteride, an inhibitor of 5α-reductase, the enzyme necessary for the conversion of testosterone to 5α-dihydrotestosterone (DHT), using the nontumorigenic rat prostatic epithelial cell line NRP-152. Growth of these cells was stimulated three- to sixfold over control by either testosterone or DHT under serum-free culture conditions. This was accompanied by a two- to threefold decrease in the secretion rate of TGF-β1, -β2, and -β3. Finasteride reversed the ability of testosterone but not DHT to stimulate growth and downregulate expression of TGF-β1, -β2, and -β3 in a dose-dependent fashion, suggesting that this activity of testosterone required its conversion to DHT. OHF antagonized the stimulatory effects of DHT on NRP-152 cell growth but could reverse the inhibitory effects of DHT only on TGF-β2 and TGF-β3 and not TGF-β1 secretion. This suggests that either TGF-β1 regulation by DHT or the androgen antagonism of OHF occurs independent of androgen receptor binding. Neutralizing antibodies to TGF-β (pantropic and isoform-specific) were able to block the ability of finasteride to antagonize the effects of testosterone nearly completely while only partially inhibiting the antiandrogenic effects of OHF. Thus, the ability of androgens to stimulate growth of NRP-152 cells involves the downregulation of the production of TGF-β1, -β2, and -β3 in addition to other growth-stimulatory mechanisms. J. Cell. Physiol. 175:184–192, 1998. Published 1998 Wiley-Liss, Inc. 1 This article is a US Government work and, as such, is in the public domain in the United States of America.Keywords
This publication has 31 references indexed in Scilit:
- Modulation of Sensitivity to Transforming Growth Factor-β1 (TGF-β1) and the Level of Type II TGF-β Receptor in LNCaP Cells by DihydrotestosteroneExperimental Cell Research, 1996
- Steroid-growth factor interaction in human prostate cancer. 1. Short-term effects of transforming growth factors on growth of human prostate cancer cellsSteroids, 1994
- The Mechanism of Action of Steroid Hormones: A New Twist to an Old TaleThe Journal of Clinical Pharmacology, 1993
- Physiological Actions and Clinical Applications of Transforming Growth Factor-β (TGF-β)Growth Factors, 1993
- Alterations in mrna levels for growth-related genes after transplantation into castrated hosts in oncogene-induced clonal mouse prostate carcinomaMolecular Carcinogenesis, 1992
- Regulation of growth of LNCaP human prostate tumor cells by growth factors and steroid hormonesThe Journal of Steroid Biochemistry and Molecular Biology, 1991
- The Transforming Growth Factor-beta FamilyAnnual Review of Cell Biology, 1990
- Differential effects of transforming growth factor β on human prostate cancer cells in vitroMolecular and Cellular Endocrinology, 1989
- Distribution and modulation of the cellular receptor for transforming growth factor-beta.The Journal of cell biology, 1987
- Androgen‐dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaPThe Prostate, 1986